Back to mobile site

Needham & Company Reiterates a 'Buy' on OncoGenex (OGXI); Stock is Undervalued

August 8, 2011 8:30 AM EDT Send to a Friend
Needham & Company reiterates a 'Buy' on OncoGenex Pharmaceuticals (NASDAQ: OGXI) price target of $26.00.

Needham analyst says, "We believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login